Clinical trial Recruiting at 4 sites Observational Ages 18 to 80

Prognostic model for Acute Respiratory Distress Syndrome using Electrical Impedance Tomography

Official title: Electrical Impedance Tomography-Based Prognostic Model for ARDS: A Multicenter, Prospective, Observational Study

Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT06967207 · Data updated 2026-11-12

This study is trying to see if a new way of measuring lung function can help doctors predict how well patients with Acute Respiratory Distress Syndrome (ARDS) will do and tailor their treatment accordingly.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment625 (estimated)
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Academic / other
Locations4 sites (Guangzhou, Guangdong and 3 other locations)
StatusRecruiting
StartedApril 15, 2025
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedMay 13, 2025
Trial IDNCT06967207 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18-80 who meet the new 2023 ARDS global definition.

Probably not a fit

Patients expected to die within 24 hours of screening or those with severe comorbidities such as metastatic cancer or chronic respiratory failure may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective, observational study aims to develop and validate a prognostic model for Acute Respiratory Distress Syndrome (ARDS) using Electrical Impedance Tomography (EIT). The study focuses on understanding the pathophysiological characteristics of ARDS and the causes of ventilator-induced lung injury. By revealing lung injury and heterogeneity, the model seeks to enable risk stratification and guide individualized treatment for patients with ARDS.

Why it matters

Potential benefit: If successful, this model could lead to improved risk assessment and personalized treatment strategies for patients with ARDS.

How similar studies have gone: While the approach using EIT for prognostic modeling in ARDS is innovative, similar studies have shown promise in understanding lung injury dynamics.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Meet the new 2023 ARDS global definition;
2. Age 18-80 years

Exclusion Criteria:

1. Expected death within 24 hours of screening;
2. Metastatic cancer (active malignancy with distant metastases);
3. Severe psychiatric disorders;
4. Pregnancy or postpartum status;
5. Pneumothorax or moderate to large pleural effusion without adequate drainage;
6. Chronic respiratory failure;
7. Patients with pulmonary embolism or pulmonary hypertension;
8. Heart failure patients: EF \<50% or NYHA class III or IV;
9. Patient/family refusal to participate;
10. Participation in another interventional trial within 3 months prior to enrollment

Where it's running

  • Department of Critical Care Medicine, Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
  • Department of Critical Care Medicine, Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
    Recruiting
  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China Department of
    Wuhan, Hubei, China
    Recruiting
  • Department of Emergency, Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.